Clopidogrel The preferred long-term antiplatelet strategy

Researchers conducted a systematic review and individual patient meta-analysis of seven randomized trials comparing clopidogrel monotherapy with aspirin for secondary prevention in 28,982 patients with coronary artery disease (CAD) from Asia (66.8 per cent), Europe (17.4 per cent), and North America (15.8 per cent).

- 

The participants had a median age of 65.5 years, 21.4 per cent were women, and around half had a prior myocardial infarction (MI), while almost a third (30.6 per cent) had Diabetes. Acute coronary syndrome was the main cause of CAD, at a rate of 68.4 per cent, and 71.0 per cent of patients had previously undergone coronary intervention.